Sequentify
Rehovot, Israel· Est.
Fast, affordable NGS library prep for high‑throughput targeted sequencing.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $7M
AI Company Overview
Fast, affordable NGS library prep for high‑throughput targeted sequencing.
OncologyGenetic DisordersDiagnostics
Technology Platform
InfiniSeq is a rapid, four‑step, 3.15‑hour targeted NGS library preparation system that integrates probe capture and amplicon concepts, allowing sample pooling after the first step and delivering platform‑agnostic libraries.
Opportunities
Rapidly expanding NGS demand in clinical diagnostics and research, especially for targeted panels, positions Sequentify to capture market share with its cost‑effective, high‑throughput library prep solution.
Risk Factors
Competition from established NGS library prep providers and the need to transition from RUO to regulated clinical use could limit adoption.
Competitive Landscape
Key competitors include Illumina, Thermo Fisher, Agilent, and Twist Bioscience; Sequentify differentiates through its unique pooling‑after‑first‑step workflow, short turnaround time, and platform‑agnostic design.